| Index bDMARD | Proportion of first-line bDMARD cohort who switched bDMARD during post-index period | Proportion of second-line bDMARD cohort who switched bDMARD during post-index period | ||
|---|---|---|---|---|
| Study 1 | Study 2 | Study 1 | Study 2 | |
| Adalimumab | 9.5% | 10.5%* | 16.7% | 19.1%* |
| Etanercept | 9.0% | 9.5% | 14.4% | 17.4% |
| Infliximab | 5.5% | 10.3% | 14.3% | 22.7%* |
| Abatacept | 2.1% | 6.5% | 8.0% | 12.6% |
↵* p<0.05 vs abatacept.